B.R.I.D.G.E. TO DATA is a unique one-stop for all databases you might need for any research purpose. A unique user-friendly directory to search for databases from all over the world, you can easily grasp what each database can offer you without wasting time on each one.
We are excited to introduce the Norwegian Surveillance System for Communicable Diseases as our 400th profile. Established in 1975, the system relies on the reporting of infectious diseases from healthcare providers and laboratories across the country. The data collected are used to develop public health policies, monitor disease trends, and respond to outbreaks.
2022 had us busy profiling databases from around the world (currently 400), including the first ones from six countries. We made several enhancements and also lowered the “global” subscription rate to make our resource more affordable to locate databases of interest. Would you complete our 2-minute survey regarding how you could benefit from B.R.I.D.G.E.?
Christina Bergland
Executive Director, Division of Health Data and Digitalisation
Norwegian Institute of Public Health
NORWAY
Email: Christine.Bergland@fhi.no
For data access, send an email to datatilgang@fhi.no
General contact information for MSIS -
Phone: (+47) 2107 7000
1. Tipu JH, Sivertsen A, Afset JE, Sandven L, Brekke H, Lund HM, Elburg LS, Gaustad P, Lier T, Tverelv LR, Johansen ØH. Cryptosporidium species and subtypes in Norway: predominance of C. parvum and emergence of C. mortiferum. Emerging Microbes & Infections. 2024 Dec 31;13(1):2412624.
2. Tunheim G, Fossum E, Robertson AH, Rø GØ, Chopra A, Vaage JT, Vikse EL, Kran AM, Magnus P, Trogstad L, Mjaaland S. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults. BMC Infectious Diseases. 2024 Aug 20;24(1):841.
3. Trinh NT, Houghtaling J, Bernal FL, Hayati S, Maglanoc LA, Lupattelli A, Halvorsen L, Nordeng HM. Harmonizing Norwegian registries onto OMOP common data model: Mapping challenges and opportunities for pregnancy and COVID-19 research. International Journal of Medical Informatics. 2024 Aug 14:105602.
4. Salamanca BV, Cyr PR, Bentdal YE, Watle SV, Wester AL, Strand ÅM, Bøås H. Increase in invasive group A streptococcal infections (iGAS) in children and older adults, Norway, 2022 to 2024. Eurosurveillance. 2024 May 16;29(20):2400242.
5. Jore S, Viljugrein H, Hjertqvist M, Dub T, Mäkelä H. Outdoor recreation, tick borne encephalitis incidence and seasonality in Finland, Norway and Sweden during the COVID-19 pandemic (2020/2021). Infection Ecology & Epidemiology. 2023 Dec 31;13(1):2281055.
6. Hetlevik Ø, Wensaas KA, Baste V, Emberland KE, Özgümüs T, Håberg SE, Rortveit G. Prevalence and predictors of post-COVID-19 symptoms in general practice-a registry-based nationwide study. BMC Infectious Diseases. 2023 Oct 25;23(1):721.
7. Gravningen K, Nymark P, Wyller TB, Kacelnik O. A new automated national register-based surveillance system for outbreaks in long-term care facilities in Norway detected three times more severe acute respiratory coronavirus virus 2 (SARS-CoV-2) clusters than traditional methods. Infection Control & Hospital Epidemiology. 2023 Sep;44(9):1451-7.
8. Whittaker R, Toikkanen S, Dean K, Lyngstad TM, Buanes EA, Kløvstad H, Paulsen TH, Seppälä E. A comparison of two registry-based systems for the surveillance of persons hospitalised with COVID-19 in Norway, February 2020 to May 2022. Eurosurveillance. 2023 Aug 17;28(33):2200888.
9. Caspersen IH, Trogstad L, Galanti MR, Karvonen S, Peña S, Shaaban AN, Håberg SE, Magnus P. Current tobacco use and SARS-CoV-2 infection in two Norwegian population-based cohorts. BMC Public Health. 2023 May 10;23(1):846.
10. Skagseth H, Jørgensen SB, Reilly J, Kacelnik O. A new method for near real-time, nationwide surveillance of nosocomial COVID-19 in Norway: providing data at all levels of the healthcare system, March 2020 to March 2022. Eurosurveillance. 2023 Mar 23;28(12):2200493.
Starting in 1997, the Icelandic Register of Communicable Diseases includes diseases, agents causing diseases and events, immunisations, and use of antimicrobial drugs, and is intended to be of use in preventive measures and in epidemiological research. Notifiable communicable diseases which can pose a threat to public welfare are subject to registration.
Sigríður Haralds Elínardóttir
Head of Division, Health Information
Directorate of Health
Katrínartún 2
IS – 105 Reykjavík
ICELAND
Phone: +354 510 1900
Email: sigridur.haraldsd.elinardottir@landlaeknir.is
Directorate of Health
Katrínartún 2
105 Reykjavík
Kt. 710169-5009
ICELAND
Tel: + 354 510 1900
E-mail: mottaka@landlaeknir.is
N/A
Academia / Nonprofits / Government agencies always get a discounted rate, as do companies that let us profile their population healthcare databases/registries in our resource. In addition, if you sign up for Unlimited Users worldwide for 2 or more years, you can receive a 10% discount (pre-paid)! Finally, licensing our B.R.I.D.G.E.
With registrations starting back in 1948, the National Cancer Registration and Analysis Service (NCRAS) is run by the National Disease Registration Service (NDRS) which is part of NHS England. It is responsible for cancer registration in England to support cancer epidemiology, public health, service monitoring and research. NCRAS is responsible for systematic collection of data about cancer and tumour diseases in England.
Sarah Stevens
Associate Director for NDRS
(National Disease Registration Service)
Email: sarah.stevens1@nhs.net
If you cannot reach the database manager, you may contact the organization by completing the contact form at:
https://digital.nhs.uk/ndrs/ndrs-contact-page
1. Webster L, Lawton S, Thackray K, Barclay M, Bomb M, Lyratzopoulos G, Dodwell D, Kipps E. The impact of the COVID-19 pandemic on the use of systemic therapy for patients diagnosed with cancer in England: A population-based study with a focus on breast and lung cancer. Cancer Epidemiology. 2025 Jun 1;96:102806.
2. Abiodun AT, Ju C, Welch CA, Lai J, Tyrer F, Chambers P, Paley L, Vernon S; NICOR Collaborative; Deanfield J, de Belder M, Rutherford MJ, Lambert PC, Slater S, Shiu KK, Wei L, Peake MD, Adlam D, Manisty C. Fluoropyrimidine Chemotherapy and the Risk of Death and Cardiovascular Events in Patients With Gastrointestinal Cancer. JACC CardioOncol. 2025 Jun;7(4):345-356.
3. Roberts K, Cooper N, Webster L, Sharpless B, Round T, Gildea C, Nicholson BD. Characterising the volume and variation of multiple urgent suspected cancer referrals in England, April 2013–March 2018: a national cohort study. BMJ open. 2025 Apr 1;15(4):e097180.
4. Swanton C, Bachtiar V, Mathews C, Brentnall AR, Lowenhoff I, Waller J, Bomb M, McPhail S, Pinches H, Smittenaar R, Hiom S. NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants. Clinical Trials. 2025 Apr;22(2):227-38.
5. Trama A, Geerdes EE, Demuru E, De Angelis R, Karim-Kos HE, Troussard X, Bennett D, Marcos-Gragera R, Kuehni CE, Liu H, Bernasconi A. Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: results from EUROCARE-6, a population-based study. European Journal of Cancer. 2025 Mar 1:115336.
6. Di Carlo V, Eberle A, Stiller C, Bennett D, Katalinic A, Marcos-Gragera R, Girardi F, Larønningen S, Schultz A, Lima CA, Coleman MP. Sex differences in survival from melanoma of the skin: The role of age, anatomic location and stage at diagnosis: A CONCORD-3 study in 59 countries. European Journal of Cancer. 2025 Feb 25;217:115213.
7. Hassan H, Rahman T, Bacon A, Knott C, Allen I, Huntley C, Loong L, Walburga Y, Morris E, Hardy S, Torr B. Long-term outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer. BMJ oncology. 2025 Feb 25;4(1):e000574.
8. Botta L, Didonè F, Lopez-Cortes A, Nieto AC, Desandes E, Hjalgrim LL, Jakab Z, Stiller CA, Zeller B, Gatta G, Pritchard-Jones K. International benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study. The Lancet Child & Adolescent Health. 2025 Feb 1;9(2):89-99.
9. Falcaro M, Castañón A, Ndlela B, Sasieni P. Association between HPV vaccination and cervical screening policy changes and cervical cancer incidence and grade-3 cervical intraepithelial neoplasia incidence in England, 2006–2020: a population-based trends analysis. The Lancet Regional Health–Europe. 2025 Feb 1;49.
10. Mumford L, Hogg R, Taylor A, Lanyon P, Bythell M, McPhail S, Chilcot J, Powter G, Cooke GS, Ward H, Thomas H. Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study. The Lancet. 2025 Jan 25;405(10475):314-28.
